Given the overlapping of neuropathological, neurochemical and neuropsychiatric profiles of Parkinson’s disease dementia (PDD), dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD), their differential diagnosis is challenging. Specific neuropsychiatric features or biomarkers, such as cerebrospinal fluid (CSF) α-Synuclein (α-Syn), may aid in differential diagnosis. This study aims to compare the neuropsychiatric and CSF α-Syn profiles in these conditions, and to investigate the possible association between CSF α-Syn levels and neuropsychiatric symptoms.
We conducted a prospective cross-sectional study, between January 2013 and January 2015, with 16 PDD, 28 DLB and 19 AD patients. All participants underwent a detailed clinical, neuropsychological, neuropsychiatric [Neuropsychiatric Inventory (NPI)] and CSF α-Syn analysis.
Significantly greater NPI Hallucinations Subitem score was found in the PDD and DLB groups compared to AD (both p < 0.001). NPI Agitation score was greater in the DLB compared to PDD group (p = 0.012). NPI Sleep score was greater in the DLB compared to AD group (p = 0.001). Total NPI score was greater in the DLB compared to AD and PDD groups. To discriminate between the DLB and AD and between DLB and PDD groups, logistic regression analysis showed that both NPI scores and α-Syn levels were independently associated. There was no correlation between NPI scores and α-Syn levels. Increased NPI scores and α-Syn levels are associated with greater likelihood for being in DLB than in PDD or AD groups. ROC analysis showed that the combination of NPI and α-Syn increases the discriminative ability of each marker alone (p < 0.001) with AUC equal to 0.95 (95% CI 0.91–0.99).
NPI scores and CSF α-Syn levels were useful as independent variables to differentiate DLB from PDD and AD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Aarsland D, Rongve A, Nore SP et al (2008) Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 26(5):445–452
Berg D, Postuma RB, Bloem BP et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462
Mandal PK, Pettegrew JW, Masliah E et al (2006) Interaction between Ab peptide and a synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31:1153–1162
Hepp DH, Vergoossen DL, Huisman E et al (2016) Distribution and load of amyloid-β pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol 75(10):936–945
Starkstein SE, Sabe L, Petracca G et al (1996) Neuropsychological and psychiatric differences between Alzheimer’sdisease and Parkinson’s disease with dementia. J Neurol Neurosurg Psychiatry 61:381–387
Kao AW, Racine CA, Quitania LC et al (2009) Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Alzheimer Dis Assoc Disord 23:365–370
Aarsland D, Cummings JL, Larsen JP (2001) Neuropsychiatric difference between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 16:184–191
Noe E, Marder K, Bell KL (2004) Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 19:60–67
Aarsland D, Ballard C, Larsen JP, Mckeith J (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 16:528–536
Chiu PY, Tsai CT, Chen PK et al (2016) Neuropsychiatric symptoms in Parkinson’s disease dementia are more similar to Alzheimer’s disease than dementia with Lewy bodies: a case-control study. PLoS One 11(4):e0153989
Hall S, Öhrfelt A, Constantinescu R et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 69:1445
Wennström M, Surova Y, Hall S et al (2013) Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8:e53250
Reesink FE, Lemstra AW, van Dijk KD et al (2010) CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis 22:87–95
Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K (2013) The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 8(11):e81654
Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707
McKeith IG, Dickson DW, Lowe J et al (2005) Consortium on DLB, diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872
McKhann Guy M, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:263–269
Politis AM, Mayer LS, Passa M et al (2004) Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer’s disease: a study of disturbing behaviors among referrals to a memory clinic. Int J Geriatr Psychiatry 19:203–208
Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414
Folstein M, Folstein S, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
del Campo M, Mollenhauer B, Bertolotto A et al (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 6:419–430
Emmanouilidou E, Elenis D, Papasilekas T et al (2011) Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One 6(7):e22225
Tateno F, Sakakibara R, Kawai T et al (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26(3):213–216
Perry RH, Irving D, Blessed G et al (1995) Senile dementia of Lewy body type. A clinically and neuropathologically distinct type of Lewy body dementia in the elderly. J Neurol Sci 95:119–139
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors report no financial disclosures.
Conflicts of interest
All authors have no interest to declare.
This study conformed to the Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Greek government and was approved by the Ethics Committee of National and Kapodistrian University Graduate School of Medicine. This study does not involve any methods or experiments with animals.
All study participants provided informed consent prior to inclusion in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Bougea, A., Stefanis, L., Paraskevas, G.P. et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 265, 2295–2301 (2018). https://doi.org/10.1007/s00415-018-8992-7
- Parkinson’s disease dementia (PDD)
- Dementia with Lewy bodies (DLB)
- Alzheimer’s disease (AD)
- Neuropsychiatric Inventory (NPI)
- α-Synuclein (α-Syn)